000302117 001__ 302117
000302117 005__ 20250819095451.0
000302117 0247_ $$2doi$$a10.1007/s11523-025-01160-6
000302117 0247_ $$2pmid$$apmid:40526350
000302117 0247_ $$2ISSN$$a1776-2596
000302117 0247_ $$2ISSN$$a1776-260X
000302117 037__ $$aDKFZ-2025-01249
000302117 041__ $$aEnglish
000302117 082__ $$a610
000302117 1001_ $$00000-0001-5411-7288$$aRiemann, Layla Tabea$$b0
000302117 245__ $$aStreamlining and Accelerating the Molecular Tumor Board Process at the University Medical Center Hamburg-Eppendorf.
000302117 260__ $$aParis$$bSpringer Verlag France S.A.R.L.$$c2025
000302117 3367_ $$2DRIVER$$aarticle
000302117 3367_ $$2DataCite$$aOutput Types/Journal article
000302117 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755590064_6402
000302117 3367_ $$2BibTeX$$aARTICLE
000302117 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302117 3367_ $$00$$2EndNote$$aJournal Article
000302117 500__ $$aVolume 20, pages 725–735
000302117 520__ $$aWe developed, introduced, and evaluated Molecular ONcology Optimized CLinical Evaluation (MONOCLE), a secure, open-source web application at the University Medical Center Hamburg-Eppendorf (UKE), to optimize the analysis and discussion of complex cancer cases in molecular tumor boards (MTB).MONOCLE standardizes and harmonizes documentation, while its integrated Knowledge Connector accelerates literature research for personalized treatment.The system was designed by merging the requirements of the German Network for Personalized Medicine (DNPM), the medical staff involved in the MTB process, and the team developing MONOCLE. The usability was evaluated using the System Usability Scale (SUS) and user tasks. Overall process optimization was measured by the number of automated tasks that can be performed.MONOCLE, introduced into clinical practice in June 2024, significantly reduces time for documentation, as three manual steps now run automatically, and transfer of the data to the DNPM is possible. Its usability and SUS showed positive results, ranging between 92.5 and 97.5.As the first open-source and extendable solution for standardized MTB documentation, MONOCLE enables wider adoption by other medical centers.
000302117 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000302117 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302117 7001_ $$aAtaian, Maximilian$$b1
000302117 7001_ $$00009-0008-0961-3280$$aHähner, Felicia P S$$b2
000302117 7001_ $$0P:(DE-He78)535b205a5a11ddcc83a9301bd41a83f1$$aRoth, Benjamin$$b3$$udkfz
000302117 7001_ $$0P:(DE-He78)d86248f91d13930d4a6ee02207362576$$aKnurr, Alexander$$b4$$udkfz
000302117 7001_ $$aKamitz, Anne$$b5
000302117 7001_ $$00000-0003-4627-0412$$aChristopeit, Maximilian$$b6
000302117 7001_ $$00000-0001-6071-7810$$aBokemeyer, Carsten$$b7
000302117 7001_ $$aÜckert, Frank$$b8
000302117 773__ $$0PERI:(DE-600)2222136-0$$a10.1007/s11523-025-01160-6$$p725–735$$tTargeted oncology$$v20$$x1776-2596$$y2025
000302117 909CO $$ooai:inrepo02.dkfz.de:302117$$pVDB
000302117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)535b205a5a11ddcc83a9301bd41a83f1$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000302117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d86248f91d13930d4a6ee02207362576$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000302117 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000302117 9141_ $$y2025
000302117 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000302117 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000302117 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTARGET ONCOL : 2022$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000302117 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bTARGET ONCOL : 2022$$d2024-12-27
000302117 9201_ $$0I:(DE-He78)M130-20160331$$kM130$$lClinical Trial Office$$x0
000302117 980__ $$ajournal
000302117 980__ $$aVDB
000302117 980__ $$aI:(DE-He78)M130-20160331
000302117 980__ $$aUNRESTRICTED